Home » AMERSIN ENTERS INTO TERMINATION AGREEMENT WITH CHINESE JOINT VENTURE PARTNER
AMERSIN ENTERS INTO TERMINATION AGREEMENT WITH CHINESE JOINT VENTURE PARTNER
Amersin Life Science Corporation (OTCBB:AMLSE) announced today that it has reached
a termination agreement and will be disposing of its interest in the Hubei Tongji
Benda Ebei Pharmaceutical Co. Ltd. joint venture in the Hubei Province of China.
Under the terms of the agreement Amersin will return its interest in the joint
venture to Benda Science and Technology Company in exchange for $220,000 to be
paid within six months and the return of 1.6 million shares of Amersin common
stock to treasury. Additional details may be found on Form 8-K filed with the
Securities and Exchange Commission this date.one
PrimeZone
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May